New progress in diagnostic techniques for hyperparathyroidism in nuclear medicine

Abstract

Hyperparathyroidism (HPT) is an endocrine system disease, which is often divided into primary hyperparathyroidism (PHPT) and secondary hyperparathyroidism (SHPT). At present, HPT has gradually become a common disease of endocrine system, and the common treatment is surgical resection of related lesions. Therefore, accurate location and detection are very important for the surgical treatment and prognosis of HPT. Therefore, the author reviews the relevant imaging examination in the field of nuclear medicine to provide help for clinical diagnosis and treatment.

Keywords

Hyperparathyroidism / Radionuclide tracing imaging / Dual tracer subtraction planar imaging / Positron emission tomography / Bone mineral density / ^99mTc-MIBI

References

[1] Cetani F, Marcocci C, Torregrossa L, et al. Atypical parathyroid adenomas: challenging lesions in the differential diagnosis of endocrine tumors. Endocrine-Related Cancer. 2019; 26(7): R441-R464. PMid:31085770. https://doi.org/10.1530/ERC-19-0135

[2] Fraser WD. Hyperparathyroidism. Lancet (London, England). 2009; 374: 145-58.https://doi.org/10.1016/S0140-6736(09)60507-9

[3] Singh O, Naykky M, et al. Outcomes of Parathyroidectomy in Patients with Primary Hyperparathyroidism: A Systematic Review and Meta-analysis. World Journal of Surgery. 2016; 40(10): 2359-77. PMid:27094563. https://doi.org/10.1007/s00268-016-3514-1

[4] Lau WL, Obi Y, Kalantar-Zadeh K. Parathyroidectomy in the Management of Secondary Hyperparathyroidism. Clinical journal of the American Society of Nephrology. CJASN. 2018; 13(6): 952-961. PMid:29523679. https://doi.org/10.2215/CJN.10390917

[5] Ritter CS, Haughey BH, Miller B, et al. Differential gene expres-sion by oxyphil and chief cells of human parathyroid glands. The Journal of Clinical Endocrinology and Metabolism. 2012; 97(8): E1499-E1505. PMid:22585091. https://doi.org/10.1210/jc.2011-3366

[6] Xue J, Liu Y, Yang D, et al. Dual-phase 99mTc-MIBI imaging and the expressions of P-gp, GST-π and MRP 1 in hyperparathy-roidism. Nuclear Medicine Communications. 2017; 38(10): 868-874. PMid:28806349. https://doi.org/10.1097/MNM.0000000000000721

[7] Treglia G, SadeghiR, Schalin-Jäntti C, et al. Detection rate of (99m) Tc-MIBI single photon emission computed tomography (SPECT)/CT in preoperative planning for patients with primary hyperparathy- roidism: A meta-analysis. Head & neck. 2016; 38(Suppl 1): E2159-E2172. PMid:25757222. https://doi.org/10.1002/hed.24027

[8] Rep S, Lezaic L, Kocjan T, et al. Optimal scan time for evalua- tion of parathyroid adenoma with [(18)F]-fluorocholine PET/CT. Radiology and oncology. 2015; 49(4): 327-333. PMid:26834518. https://doi.org/10.1515/raon-2015-0016

[9] Kluijfhout WP, Vorselaars WM, Vriens MR, et al. Enabling minimal invasive parathyroidectomy for patients with primary hyperparathy- roidism using Tc-99m-sestamibi SPECT-CT, ultrasound and first results of (18)F-fluorocholine PET-CT. European journal of radiology. 2015; 84(9): 1745-1751. PMid:26047823. https://doi.org/ 10.1016/j.ejrad.2015.05.024

[10] Wong KK, Fig LM, Gross MD, et al. Parathyroid adenoma local- ization with 99mTc-sestamibi SPECT/CT: a meta-analysis. Nuclear medicine communications. 2015; 36(4): 363-375. PMid:25642803. https://doi.org/10.1097/MNM.0000000000000262

[11] Carral F, Jiménez AI, Tomé M, et al. Factors associated with negative 99mTc-MIBI scanning inpatients with primary hyperparathyroidism. Revista espanola de medicina nuclear e imagen molecular. 2021; 40(4): 222-228. PMid:34218884. https://doi.org/10.1016/j.remn.2020.07.001

[12] Petranović Ovčariček, Giovanella P, Carrió Gasset L, et al. The EANM practice guidelines for parathyroid imaging. European journal of nuclear medicine and molecular imaging. 2021; 48(9): 2801-2822. PMid:33839893. https://doi.org/10.1007/s00259-021-05334-y

[13] Zhang M, et al. The value of semi-quantitative measurement of 99mTc-MIBI uptake for differentiating malignant from benign parathyroid lesions in patients with PHPT. The Journal of Nuclear Medicine. 2018; 59.

[14] Treglia G, SadeghiR, Schalin-Jäntti C, et al. Detection rate of (99m) Tc-MIBI single photon emission computed tomography (SPECT)/CT in preoperative planning for patients with primary hyperparathy- roidism: A meta-analysis. Head & neck. 2016; 38(Suppl 1): E2159-E2172. PMid:25757222. https://doi.org/10.1002/hed.24027

[15] Shafiei B, Hoseinzadeh S, Fotouhi F, et al. Preoperative 99mTc- sestamibiscintigraphy in patients with primary hyperparathyroidism and concomitant nodular goiter: comparison of SPECT-CT, SPECT, and planar imaging. Nuclear medicine communications. 2012; 33(10): 1070-1076. PMid:22825041. https://doi.org/10.1097/MNM.0b013e32835710b6

[16] Zhen L, Li H, Liu X, et al. The application of SPECT/CT for preoperative planning in patients with secondary hyperparathy- roidism. Nuclear medicine communications. 2013; 34(5): 439-444. PMid:23458854. https://doi.org/10.1097/MNM.0b013e32835f9447

[17] Kunstman JW, Kirsch JD, MahajanA, et al. Clinical review: Parathy- roid localization and implications for clinical management. The Journal of clinical endocrinology and metabolism. 2013; 98(3): 902-912. PMid:23345096. https://doi.org/10.1210/jc.2012-3168

[18] Nichols KJ, Tomas MB, Tronco GG, et al. Sestamibi parathyroid scintigraphy in multigland disease. Nuclear medicine communica- tions. 2012; 33(1): 43-50. PMid:22001718. https://doi.org/10.1097/MNM.0b013e32834bfeb1

[19] Woods AM, Bolster AA, Han S, et al. Dual-isotope subtraction SPECT-CT in parathyroid localization. Nuclear medicine communications. 2017; 38(12): 1047-1054. PMid:28984813. https://doi.org/10.1097/MNM.0000000000000765

[20] Giovanella L, Avram AM, Iakovou I, et al. EANM practice guide- line/SNMMI procedure standard for RAIU and thyroid scintigraphy. European journal of nuclear medicine and molecular imaging. 2019; 46(12): 2514-2525. PMid:31392371. https://doi.org/10.1007/s00259-019-04472-8

[21] Quak E, Lheureux S, Reznik Y, et al. F18-choline, a novel PET tracer for parathyroid adenoma?. The Journal of clinical endocrinol- ogy and metabolism. 2013; 98(8): 3111-3112. PMid:23788686. https://doi.org/10.1210/jc.2013-2084

[22] Fukumoto M. Single-photon agents for tumor imaging: 201Tl, 99mTc-MIBI, and 99mTc-tetrofosmin. Ann Nucl Med. 2004; 18: 79-95. PMid:15195755. https://doi.org/10.1007/BF02985098

[23] Vallabhajosula S. (18)F-labeled positron emission tomographic radiopharmaceuticals in oncology: an overview of radiochemistry and mechanisms of tumor localization. Semin NuclMed. 2007; 37: 400-419. PMid:17920348. https://doi.org/10.1053/j.semnuclmed.2007.08.004

[24] Ishizuka T, Kajita K, Kamikubo K, et al. Phospholipid/Ca²⁺ - dependent protein kinase activity in human parathyroid adenoma. Endocrinol Jpn. 1987; 34: 965-968. PMid:3450512. https://doi.org/10.1507/endocrj1954.34.965

[25] Whitman J, Allen IE, Bergsland EK, et al. Assessment and Com- parison of 18F-Fluorocholine PET and 99mTc-Sestamibi Scans in Identifying Parathyroid Adenomas: A Metaanalysis. Journal of nuclear medicine: official publication, Society of Nuclear Medicine. 2021; 62(9): 1285-1291. PMid:33452040. https://doi.org/10.2967/jnumed.120.257303

[26] Lezaic L, Rep S, Sever MJ, et al. 18F-Fluorocholine PET/CT for localization of hyperfunctioning parathyroid tissue in primary hyper-parathyroidism: a pilot study. European journal of nuclear medicine and molecular imaging. 2014; 41(11): 2083-2089. PMid:25063039. https://doi.org/10.1007/s00259-014-2837-0

[27] Triantafyllidou M, Strobel K, Leiser A, et al. Localisation of ec- topic mediastinal parathyroid adenoma by 18F-fluorocholine PET/CT. BMJ case reports. 2018; bcr2017222089. PMid:29592976. https://doi.org/10.1136/bcr-2017-222089

[28] RepS, Hocevar M, VaupoticJ, et al. 18F-choline PET/CT for parathy- roid scintigraphy: significantly lower radiation exposure of patients in comparison to conventional nuclear medicine imaging approaches. Journal of radiological protection: official journal of the Society for Radiological Protection. 2018; 38(1): 343-356. PMid:29339573. https://doi.org/10.1088/1361-6498/aaa86f

[29] Broos W, Wondergem M, Knol R, et al. Parathyroid imaging with 18F-fluorocholine PET/CT as a first-line imaging modality in pri- mary hyperparathyroidism: a retrospective cohort study. EJNMMI research. 2019; 9(1): 72. PMid:31367807. https://doi.org/10.1186/s13550-019-0544-3

[30] Boccalatte LA, Gómez NL, Olivera López S, et al. Hiper- paratiroidismo ectópico. Detección dela localización mediastinal [Ectopic hyperparathyroidism. Detection of mediastinal localization]. Medicina. 2020; 80(1): 39-47.

[31] Hocevar M, Lezaic L, Rep S, et al. Focused parathyroidectomy with- out intraoperative parathormone testing is safe after pre-operative localization with 18F-Fluorocholine PET/CT. European journal of surgical oncology: the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. 2017; 43(1): 133-137. PMid:27776943. https://doi.org/10.1016/j.ejso.2016.09.016

[32] Piccardo A, Trimboli P, Rutigliani M, et al. Additional value of integrated 18F-choline PET/4D contrast-enhanced CT in the localization of hyperfunctioning parathyroid glands and correlation with molecular profile. European journal of nuclear medicine and molecular imaging. 2019; 46(3): 766-775. PMid:30219964. https://doi.org/10.1007/s00259-018-4147-4

[33] Caldarella C, Treglia G, Isgrò MA, et al. Diagnostic performance of positron emission tomography using 11C-methionine inpatients with suspected parathyroid adenoma: a meta-analysis. Endocrine. 2013; 43(1): 78-83. PMid:22801990. https://doi.org/10.1007/s12020-012-9746-4

[34] Kluijfhout WP, Pasternak JD, Drake FT, et al. Use of PET tracers for parathyroid localization: a systematic review and meta-analysis. Langenbeck’s archives of surgery. 2016; 401(7): 925-935. PMid:27086309. https://doi.org/10.1007/s00423-016-1425-0

[35] Weber T, Maier-Funk C, Ohlhauser D, et al. Accurate preoperative localization of parathyroid adenomas with C-11 methionine PET/CT. Annals of surgery. 2013; 257(6): 1124-1128. PMid:23478517. https://doi.org/10.1097/SLA.0b013e318289b345

[36] Hayakawa N, Nakamoto Y, Kurihara K, et al. A comparison between 11C-methionine PET/CT and MIBI SPECT/CT for localization of parathyroid adenomas/hyperplasia. Nuclear medicine communications. 2015; 36(1): 53-59. PMid:25244350. https://doi.org/10.1097/MNM.0000000000000216

[37] Levin A, Bakris GL, Molitch M, et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus inpatients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney international. 2007; 71(1): 31-38. PMid:17091124. https://doi.org/10.1038/sj.ki.5002009

[38] Rejnmark L, Ejlsmark-Svensson H. Effects of PTH and PTH Hy-persecretion on Bone: a Clinical Perspective. Current osteoporosis reports. 2020; 18(3): 103-114. PMid:32222892. https://doi.org/10.1007/s11914-020-00574-7

[39] Guo CY, Thomas WE al-Dehaimi AW, et al. Longitudinal changes in bone mineral density and bone turnover in postmenopausal women with primary hyperparathyroidism. The Journal of clinical endocrinol- ogy and metabolism. 1996; 81(10): 3487-3491. PMid:8855790. https://doi.org/10.1210/jcem.81.10.8855790

[40] Eriksen EF, Mosekilde L, Melsen F. Trabecularbone remodeling and balance in primary hyperparathyroidism. Bone. 1986; 7(3): 213-221. PMid:3768200. https://doi.org/10.1016/8756-3282(86)90020-7

[41] Rolighed L, Vestergaard P, Heickendorff L, et al. BMD improve- ments after operation for primary hyperparathyroidism. Langen-beck’s archives of surgery. 2013; 398(1): 113-120. PMid:23132462. https://doi.org/10.1007/s00423-012-1026-5

[42] Khosla S, Melton LJ 3^rd, Wermers RA, et al. Primary hyperparathy- roidism and the risk of fracture: a population-based study. Journal of bone and mineral research: the officialjournal of the American Society for Bone and Mineral Research. 1999; 14(10): 1700-1707. PMid:10491217. https://doi.org/10.1359/jbmr.1999.14.10.1700